Table 2 Dose-escalation scheme
From: A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer
S-1 dose | No. of cycles | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Level | No. of patients | Eribulin dose (mg m−2) | (mg m−2) | BSA<1.25 m 2 | 1.25 m 2 ⩽BSA<1.5 m 2 | 1.5 m 2 ⩽BSA | Median | Range | No. of patients with DLT |
1 | 3 | 1.1 | 65 | 25 mg | 40 mg | 50 mg | 2 | 2–4 | 0 |
2 | 3 | 1.4 | 65 | 25 mg | 40 mg | 50 mg | 5 | 5–9 | 0 |
3 | 6 | 1.4 | 80 | 40 mg | 50 mg | 60 mg | 7 | 1–11 | 1 |
